Search results
FDA approves Takeda's ENTYVIO for Crohn's disease
Investing.com· 7 days agoFDA approves Takeda's ENTYVIO for Crohn's disease
FDA Approves Takeda’s Subcutaneous Form of Entyvio as a Maintenance Therapy in Adults with...
Pharmaceutical Executive Magazine· 5 days agoThe FDA has approved Takeda Pharmaceuticals’ subcutaneous (SC) form of Entyvio (vedolizumab) as a...
Takeda Pharmaceutical: A Long-Term Cash Cow
GuruFocus.com via Yahoo Finance· 2 days agoSource: Author's elaboration, based on Takeda Pharmaceutical press releases. Entyvio's exclusivity is not ending anytime soon, and a potential launch of...
Takeda Says FDA Has Approved Subcutaneous Entyvio for Crohn's Disease
Market Watch· 6 days agoTakeda Pharmaceutical said the U.S. Food and Drug Administration has approved subcutaneous administration of Entyvio as a maintenance therapy for adults ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 2 weeks agoVisiongain has published a new report entitled Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034: Forecasts by Indication (Crohn's Disease, Ulcerative Colitis), by Route of Administration (Oral, Parenteral, Rectal), by Distribution
FDA OKs Sub-Q Vedolizumab for Crohn's Maintenance Therapy
Medscape· 6 days agoSubcutaneous administration of vedolizumab is now approved for maintenance therapy in adults with moderate to severe active Crohn's disease after induction therapy with intravenous vedolizumab.
Pfizer’s Velsipity UK approval to raise competition in ulcerative colitis market
BioPharma-Reporter· 1 week agoWith the approval, the drug will increase the competition in the UC market, where multiple players...
ED Doc's License Revoked; Bird Flu Fatality Rate in Humans; Pesticide Risk in Fruits
MedPage Today· 6 days agoNew Jersey revoked the medical license of emergency department (ED) doctor Shar Kennett, MD, to...
